



CathRx Ltd
ABN 23 089 310 421
5 Parkview Drive
Homebush Bay NSW 2127
Australia
Telephone +61 (0)2 9397 5700
Facsimile +61 (0)2 9397 5701
www.cathrx.com

ASX Announcement

CXD receives CE Mark approval for advanced Diagnostic “Loop” catheter used for Atrial Fibrillation

SYDNEY 1 July 2009: Cardiac catheter manufacturer CathRx Limited (ASX: CXD) today announced it had received CE Marking for its advanced diagnostic, or “Loop” catheter. The catheter will be used in atrial fibrillation procedures and is designed to be one of the most advanced catheters of its kind on the market in Europe.

Atrial Fibrillation is estimated to affect approximately 5 million people globally.

CathRx Chief Executive Officer Neil Anderson said, “The Loop catheter has been designed and purpose built for electrophysiologists treating atrial fibrillation. The ability for the catheter’s stylet to be withdrawn when required is a key safety feature.”

All of CathRx diagnostic catheters have now been approved for sale in Europe within the time required for the achievement of the Company’s sales projections of diagnostic catheters.

Regulatory efforts are now being directed towards achieving CE Mark approval for CathRx therapeutic catheters.

About CathRx

CathRx is a medical device company which manufactures and sells advanced cardiac catheter systems for the diagnosis and treatment of cardiac arrhythmias. CathRx’s proprietary diagnostic and therapeutic catheters are designed to give physicians the tools to successfully treat patients with speed, safety and precision. All of CathRx’s diagnostic products are now on sale in Europe.

About cardiac arrhythmias

Cardiac arrhythmia describes a group of increasingly common conditions where there is abnormal electrical activity in the heart. The beating of a normal heart is controlled by electrical impulses. When these impulses are uncoordinated the heart fails to function properly. This can result in complications ranging from fatigue to stroke and even death. More than 10 million people worldwide suffer from abnormal heart rhythms. Atrial fibrillation is the most common form of arrhythmia and affects over 5 million people worldwide. Current drug therapies often fail to control the problem and can have side effects. Physicians worldwide are increasingly using cardiac catheters to diagnose and successfully treat arrhythmias.

For further information:

*Neil Anderson
CathRx Chief Executive Officer
Ph: 02 9397 5700*

*Jeannene O’Day
Lyon Group
Ph: 0439 865 256*